Unknown

Dataset Information

0

Targeting autophagy potentiates antitumor activity of Met-TKIs against Met-amplified gastric cancer.


ABSTRACT: Met tyrosine kinase inhibitors (Met-TKIs) subjected to ongoing clinical trials are a promising option for Met-amplified gastric cancer (GC), but how to optimize their antitumor activity especially with combination schemes remains unclear. Since autophagy is known to be initiated by Met-TKIs, we investigated its underlying mechanisms and therapeutic potentials of Met-TKIs combined with autophagy inhibitors against Met-amplified GC. As expected, four Met-TKIs induced autophagy in Met-amplified GC cells marked by p62 degradation, LC3-II accumulation and increased LC3-positive puncta. Autophagy flux activation by Met-TKIs was further validated with combined lysosomal inhibitors, bafilomycin A1 (Baf A1) and hydroxychloroquine (HCQ). Molecular investigations reveal that autophagy induction along with mTOR and ULK1 de-phosphorylation upon Met-TKI treatment could be relieved by hepatocyte growth factor (HGF) and mTOR agonist MHY1485 (MHY), suggesting that autophagy was initiated by Met-TKIs via Met/mTOR/ULK1 cascade. Intriguingly, Met-TKIs further suppressed cell survival and tumor growth in the presence of autophagy blockade in Met-amplified GC preclinical models. Thus, these findings indicate Met/mTOR/ULK1 cascade responsible for Met-TKI-mediated autophagy and Met-TKIs combined with autophagy inhibitors as a promising choice to treat Met-amplified GC.

SUBMITTER: Lin X 

PROVIDER: S-EPMC6374362 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Targeting autophagy potentiates antitumor activity of Met-TKIs against Met-amplified gastric cancer.

Lin Xiaoting X   Peng Zhi Z   Wang Xiaojuan X   Zou Jianling J   Chen Dongshao D   Chen Zuhua Z   Li Zhongwu Z   Dong Bin B   Gao Jing J   Shen Lin L  

Cell death & disease 20190213 2


Met tyrosine kinase inhibitors (Met-TKIs) subjected to ongoing clinical trials are a promising option for Met-amplified gastric cancer (GC), but how to optimize their antitumor activity especially with combination schemes remains unclear. Since autophagy is known to be initiated by Met-TKIs, we investigated its underlying mechanisms and therapeutic potentials of Met-TKIs combined with autophagy inhibitors against Met-amplified GC. As expected, four Met-TKIs induced autophagy in Met-amplified GC  ...[more]

Similar Datasets

| S-EPMC5584279 | biostudies-literature
2016-05-13 | GSE77320 | GEO
2016-05-13 | E-GEOD-77320 | biostudies-arrayexpress
| S-EPMC7446425 | biostudies-literature
| S-EPMC8313856 | biostudies-literature
| S-EPMC3263825 | biostudies-literature
| S-EPMC7969610 | biostudies-literature
| S-EPMC10587944 | biostudies-literature
| S-EPMC8105218 | biostudies-literature
| S-EPMC4209288 | biostudies-literature